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Abstract
Aims Insulin possesses both vasodilatory and sympathomimetic activities. The aim was to examine the relationship between 
changes in insulin exposure and arterial stiffness in type 2 diabetes (T2D).
Methods Patients with T2D with (n = 22) or without (n = 24) albuminuria, and non-diabetic controls (n = 25) were rand-
omized to a crossover study having a breakfast with or without pre-meal rapid-acting insulin. Pulse wave velocity (PWV) 
was measured at 30 min before and at 60-min intervals up to 240 min after the breakfast.
Results At baseline, both postprandial aortic (p = 0.022) and brachial (p = 0.011) PWV were higher in individuals with T2D 
than in healthy controls irrespective of the presence of albuminuria. In patients with albuminuria, weight-adjusted insu-
lin dose correlated inversely with the excursion of the aortic (r = − 0.412, p = 0.006) and brachial (r = − 0.372; p = 0.014) 
PWV. Similarly, circulating endogenous insulin concentrations correlated inversely with the aortic (r = − 0.347, p = 0.026) 
and brachial (r = − 0.622, p = <0.001) PWV. No correlations between insulin and PWV were observed in patients without 
albuminuria or in healthy controls.
Conclusions The inverse correlation between insulin and PWV in T2D with albuminuria may reflect a vasorelaxing effect 
of insulin.
Clinical trial registration number The study was registered (clinicaltrials.gov) with the identifier of NCT01159938.
Keywords Type 2 Diabetes · Pulse wave velocity · Arterial stiffness · Insulin resistance · Albuminuria · Diabetic 
nephropathy · Diabetic kidney disease
Introduction
The role of insulin in enhancing peripheral blood flow as 
well as increasing arterial diameter in large arteries is well 
established [1–3]. The vasodilatory effect of insulin can be 
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blocked by inhibiting nitric oxide synthesis highlighting 
the endothelial effects of insulin [4]. It is not known if the 
vasodilatory effect of insulin is preserved in patients with 
diabetic complications. An open but important question is 
whether albuminuria, which is often related to autonomous 
neuropathy and endothelial dysfunction, influences the effect 
of insulin on blood flow and/or arterial stiffness [5–8]. In 
the absence of autonomic neuropathy, there is synchrony 
between vasodilatory and vasoconstrictive effects of insulin 
in maintaining appropriate blood flow. We have previously 
shown that postprandial hyperglycemia increases brachial 
pulse wave velocity (PWV) in albuminuric but not in nor-
moalbuminuric patients with type 2 diabetes (T2D) [9]. Now 
we analyzed whether there is any association between post-
prandial hyperinsulinemia and the stiffness of large (aortic) 
and middle-sized (brachial) arteries in individuals with T2D, 
and if so, are there differences between T2D patients with or 
without albuminuria.
Subjects, study design and methods
Subjects
Twenty-two patients with type 2 diabetes with and 24 
patients without albuminuria, and 25 non-diabetic con-
trol subjects were studied after a high-carbohydrate meal. 
Eligible individuals were male between 45 and 70 years 
of age, had not smoked in the 12 h before the visits, and 
had not experienced cardiovascular event such as coronary 
heart disease, stroke or peripheral vascular disease. All 24 
patients with albuminuria, 21/22 patients without albu-
minuria and 5/20 control subjects were on antihyperten-
sive medication. ACE inhibitors/ATII blockers were used 
by 5/10 patients, with albuminuria, 2/5 patients without 
albuminuria, and 6/1 control subject. Cholesterol-lowering 
agents (mostly statins) were used by 73% of patients with 
albuminuria, 92% of patients without albuminuria and 8% 
of the control subjects as described previously [9]. Their 
clinical characteristics are shown in Table 1. The study 
protocol is in accordance with the Declaration of Helsinki 
as revised in 2000, and approved by the local ethics com-
mittee. Written informed consent was obtained from each 
patient.
Study design
The study was performed over two single-day clinical visits. 
Patients (stratified by the presence or absence of albumi-
nuria) were randomized to two treatment schedules: either 
insulin lispro was or was not injected subcutaneously before 
a standard breakfast. The patients injected their basal insu-
lin (insulin glargine or detemir) as usual before the study. 
Healthy individuals were studied only once. Blood samples 
were drawn and PWV was measured 30 min before and 
60, 120, 180, and 240 min after the breakfast meal. The 
design and the composition of the meals have already been 
published in the previous paper [9]. In brief, this study was 
done in three single-day visits. During visit 1, the patients 
with diabetes were randomized blindly (albuminuria vs nor-
mal UAER) to have insulin lispro subcutaneously before 
Table 1  Subject characteristics
Values inside the brackets illustrate p values for pairwise comparison to healthy volunteers
BMI body mass index, UAER urinary albumin excretion




Patients with albuminuria Patients with normal UAER
N = 25 N = 22 N = 24
Age (years) 59 ± 7 61 ± 5 (0.148) 64 ± 5 (0.004)
BMI (kg/m2) 27 ± 3 34 ± 5 (< 0.001) 32 ± 6 (< 0.001)
Disease duration (years) NAa 12 ± 4 16 ± 8
UAER (ug/min) NAa 273 ± 476 5 ± 5
HbA1c (%) (mmol/mol) 5.4 ± 0.3 7.8 ± 1.3 (< 0.001) 7.4 ± 1.1 (< 0.001)
35 ± 1.5 62 ± 6.5 57 ± 5.5
Total cholesterol (mmol/l) 5.3 ± 0.8 4.1 ± 0.7 (< 0.001) 4.3 ± 0.9 (< 0.001)
Triglycerides (mmol/l) 1.3 ± 0.5 1.5 ± 0.8 (0.554) 1.6 ± 1.5 (0.401)
Insulin dose (U)
 Lispro NA 13 ± 14 11 ± 6
 Basal insulin. high PP glucose NA 80 ± 53 61 ± 49
Basal insulin. low PP glucose NA 78 ± 53 61 ± 50
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breakfast meal either during visit 2 or visit 3. The breakfast 
included 500 kcal, 60% carbohydrate, 20% protein and 20% 
fat. The day insulin lispro was injected, the rise in glucose 
was less (low-glucose study) than on the day lispro was not 
injected (high-glucose study). Insulin dosing was based on 
the patient’s normal morning insulin dose and the energy 
content of the meal. If the study breakfast was larger than the 
patient’s normal breakfast, insulin lispro dose was increased 
by 20–50% at the discretion of the investigator.
Methods
To measure the arterial stiffness in the large (carotid–femoral 
or aortic) and intermediate-sized (carotid–radial or brachial) 
arteries, PWV pressure waveforms were recorded sequentially 
at the carotid, femoral, and radial arteries with a high-fidelity 
micromanometer (SPC-301; Millar Instruments: SphygmoCor, 
Sydney Australia). With a simultaneous EKG recording of the 
R-wave as reference frame, the software calculated the PWV 
[10].
Blood glucose was measured by the glucose oxidase 
method using a HemoCue 201 m (Hemocue, Ängelholm, 
Sweden). Insulin was quantitated with a immunoelectrochemi-
luminometric assay on the Modular Analytics E170 analyzer 
(Roche Diagnostics, Mannheim, Germany). The detection 
limit of the assay is 0.2 mU/L. Intra-assay coefficient of vari-
ation is < 2% and inter-assay variation < 5% at 7–400 mU/L. 
Cross-reaction with insulin analogues lispro, aspart, glargine, 
detemir and glulisine is < 0.1% [11, 12]. The assay is cali-
brated against WHO 1st IRP NIBSC 66/304.
Statistical analyses
Pearson correlation coefficient was used to summarize the 
association between insulin and PWV. The observed area 
under the curve (AUC) (AUC 0–4h) not adjusted for baseline 
values as in our previous paper [9]) was calculated for PWV 
and the insulin concentrations. The least square (LS) means, 
obtained from an ANCOVA model (including age and BMI as 
covariates and the subject group as factor) were summarized 
separately by subject group and glycemic condition (i.e., low 
or high). The LS means were compared between the subject 
groups and the significance was assessed at the two-sided 5% 
level. Finally, to test whether insulin has a similar effect on 
PWV (similar slopes) in patients with and without albuminu-
ria and in the control group, the interaction term between the 
groups and insulin as continuous measurement was incorpo-
rated in the model. While the individuals with T2D were stud-
ied during two periods (i.e., under high- and low-postprandial 
glucose conditions), the non-diabetic controls were studied 
only for one period. The model predicted mean data per time 
point for the control group were different between the two gly-
cemic conditions due to the effect of adjusting for covariates. 
Statistical analyses were performed using SAS 9.4 version 
(SAS Institute Inc, Cary, NC, USA).
Results
Blood glucose
In the two diabetes patient groups combined, the LS 
mean ± SE glucose level was 6.8 ± 0.2  mmol/L before 
breakfast. The peak postprandial rise in blood glucose after 
breakfast was lower with (3.3 ± 0.3 mmol/L, p = 0.001) 
than without (5.3 ± 0.3 mmol/L) pre-meal lispro injection 
(p = 0.001). While the glucose levels were significantly 
higher throughout the study in both diabetes groups as com-
pared to healthy controls (p < 0.01–0.001), there were no 
differences in postprandial glucose levels between patients 
with or without albuminuria [9].
Insulin dosages and concentrations
There was no significant difference in the mean doses 
(U ± SD) of insulin lispro and basal insulin (glar-
gine or levemir) in patients with albuminuria (lispro 
13.4 ± 13.7 + basal 80.1 ± 53.3 vs 77.7 ± 53.4 basal only 
in low- and high-glucose studies, respectively) compared 
to patients without albuminuria (lispro 11.2 ± 6.1 + basal 
60.8 ± 49.5 vs 61.3 ± 50.0 basal only). Neither was there 
any significant difference in the LS mean AUC (± SE) of 
serum insulin concentrations in the high- and low-glucose 
studies, respectively, in patients with (96.4 ± 18.6 and 
84.1 ± 18.3 mU * h/L) or without albuminuria (119.2 ± 17.2 
and 102.1 ± 17.4 mU * h/L), or between the diabetes patient 
groups. In healthy individuals, the mean serum insulin AUC 
was 109.7 ± 19.7 mU * h/L, not significantly different from 
the two diabetes groups. There was no significant difference 
between the diabetic groups in insulin AUC as such, or when 
AUC was adjusted by weight.
PWV
At baseline, the LS mean (± SE) of AUC PWV in 
the aorta was higher in patients with (42.3 ± 2.4 and 
41.9 ± 2.27 m * h/s) and without albuminuria (41.2 ± 2.3 
and 41.6 ± 2.3 m * h/s) as compared to healthy controls 
(34.3 ± 2.3 and 36.0 ± 2.3 m *h/s, p = 0.022 and 0.072), 
while there was no difference between the two diabetes 
subgroups. Similarly, the LS mean (± SE) of AUC bra-
chial PWV was higher in patients with (32.1 ± 1.1 and 
32.9 ± 1.2 m * h/s) and without albuminuria (30.6 ± 1.0 
and 31.2 ± 1.2 m * h/s) as compared to healthy controls 
(27.7 ± 1.1 and 27.6 ± 1.3 m * h/s, p = 0.011 and 0.009), 
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while there was no difference between the two diabetes 
subgroups.
Correlation between insulin and PWV
In patients with albuminuria, there was a significant inverse 
correlation between total insulin dose/weight and AUC 
aortic (Fig. 1) and brachial PWV (Fig. 2). Similarly, there 
was an inverse relationship between AUC of endogenous 
serum insulin concentration and AUC aortic PWV (Fig. 3) 
and brachial PWV (Fig. 4). When glucose was included in 
these correlations (insulin dose/weight/AUC glucose vs 
AUC PWV), the significance remained in the albuminu-
ric patients for aortic (r = − 0.383, p < 0.011) and brachial 
PWV (r = − 0.372, p < 0.014). Equally, the correlations 
after adjustment for serum glucose between the AUC serum 
insulin concentration/weight/AUC glucose and the AUC 
PWV were significant in the albuminuric patients for aor-
tic (r = − 0.381, p < 0.014) and brachial PWV (r = − 0.571, 
p < 0.001). Inclusion of total cholesterol and eGFR in the 
model on top of the previous covariates did not influence 
the associations between insulin and arterial stiffness fur-
ther strengthening our results (data not shown). Notably, 
in patients without albuminuria or in healthy controls no 
such correlations between insulin and PWV were observed. 
However, the slopes were significantly different between 
patients with and without albuminuria only in case of bra-
chial PWV, as the interaction term between albuminuria 
groups and insulin was significant (p = 0.002 for both AUC 
insulin concentration, and total insulin dose). No interac-
tions were observed between controls and either of the dia-
betes groups. The data were further separately analyzed for 
high- or low-postprandial glucose conditions. The associa-
tions between brachial PWV and insulin dose/weight dur-
ing high- and low-postprandial conditions were r = − 0.543, 
p = 0.013 and − 0.659, p = 0.001, respectively. The associa-
tions between aortic PWV and insulin dose/weight during 
Fig. 1  Correlation between 
AUC aortic PWV and total 
insulin dose/weight in patients 
with type 2 diabetes with 
albuminuria. For each patient, a 
study with and without pre-meal 
lispro is included
Fig. 2  Correlation between 
AUC brachial PWV and total 
insulin dose/weight in patients 
with type 2 diabetes with 
albuminuria. For each patient, a 




high -and low-postprandial conditions were 0.574, p = 0.008 
and − 0.442, p = 0.039, respectively.
Discussion
We observed an inverse correlation between insulin and 
PWV in the T2D patients with but not without albuminuria 
or in healthy controls. Microalbuminuria is associated with 
autonomic neuropathy [6, 7] and endothelial dysfunction 
[8]. Since insulin plays a key role in the regulation of arterial 
blood flow, tone and endothelial function [13], we exam-
ined whether albuminuria influences the association between 
insulin availability and postprandial PWV in large arteries.
The correlation between postprandial arterial stiffness 
(PWV) and insulin under hyperglycemic conditions in 
patients with T2D remained statistically significant, when 
insulin dose/weight or serum insulin concentration was 
adjusted for the plasma glucose concentration suggesting 
that the association is independent of the glycemia and may 
reflect a direct insulin-medicated effect. We had a specific 
assay for endogenous insulin, but did not have a specific 
assay for lispro or insulin glargine or detemir. For this rea-
son, we used the insulin dose as a second measure of insu-
lin availability. There was an inverse correlation between 
PWV and with both endogenous insulin as well as insulin 
dose, supporting our hypothesis of a correlation between 
insulin and PWV. Surprisingly, these correlations were 
neither present in T2D patients without albuminuria nor 
in healthy individuals. The significant difference between 
the albuminuric and the non-albuminuric patients regard-
ing the correlation coefficients trends of insulin vs PWV 
further supports that insulin has a different effect on PWV in 
these two patient groups. A potential role of insulin is further 
supported by the fact that there was no difference between 
the groups regarding the prevalence of cardiovascular dis-
ease, cholesterol-lowering or antihypertensive medications. 
In this particular study, the original aim was to examine 
Fig. 3  Correlation between 
AUC aortic PWV and AUC of 
endogenous serum insulin con-
centration in patients with type 
2 diabetes with albuminuria. 
For each patient, a study with 
and without pre-meal lispro is 
included
Fig. 4  Correlation between 
AUC brachial PWV and AUC 
of endogenous serum insulin 
concentration in patients with 
type 2 diabetes with albumi-
nuria. For each patient, a study 




the effect of postprandial hyperglycemia on PWV. For this 
reason, we selected patients with type 2 diabetes, who were 
using basal–bolus regimens so that one study can be done 
with and another without pre-meal short-acting insulin. This 
design served well to examine a potential relationship of 
PWV and postprandial insulin, endogenous or exogenous. 
We could not observe differences in established biomarkers 
reflecting inflammation, endothelial function or advanced 
glycated end-products (sCRP, sICAM-1, sVCAM-1, ADMA, 
sRAGE) between the groups [9].
The finding may be explained by insulin’s dual role in 
the vasculature. Although insulin is a vasodilator, concom-
itantly it can also constrict the arteries through the auto-
nomic nervous system [5]. The balance and the shift in the 
balance of the sympatico-excitatory and the vasodilator 
effects of insulin can occur already at modestly elevated 
plasma insulin levels [9], as our patients had. One could 
anticipate that patients with T2D and albuminuria have 
advanced autonomic neuropathy [6, 7], which can dimin-
ish the vasoconstrictive effects of insulin. As a result, the 
vasodilatory effects of insulin were dominant in the cur-
rent setting resulting in a reduced PWV. Importantly, we 
can only speculate on these mechanisms as we lack direct 
measures of autonomic neuropathy in this study. Another 
contributing factor could be among patients with albu-
minuria a higher sensitivity to insulin and its vasodila-
tory effects as compared to patients without albuminuria. 
While patients were using exogenous insulin, their serum 
endogenous insulin concentrations were similar to healthy 
individuals, probably reflecting insulin resistance.
This study does not go without limitations. The study 
groups were relatively small and the correlations might 
be influenced by a few extreme observations. We have, 
therefore, presented the data in scatter plots showing the 
response of individual subjects. Regarding the insulin 
exposure, there were no differences in insulin doses or 
areas under the curves for endogenous insulin between 
albuminuric and non-albuminuric patients. Thus, differ-
ences in insulin exposure cannot explain the difference 
in the relationship of PWV and insulin in the two patient 
groups. We used the insulin dose as an approximate of 
total exogenous insulin exposure which may not be an 
exact measure. This approach was, however, consistently 
used throughout the study. We cannot exclude the fact 
that albuminuria would have been masked by the use of 
RAAS inhibitors in this real-life study. We did not have 
any specific measures of autonomic neuropathy, but it is 
well established that patients with albuminuria have a 
more advanced autonomic neuropathy than patients with-
out albuminuria [6].
In conclusion, we observed an inverse correlation 
between insulin and arterial stiffness in large (aortic) 
and middle-sized (brachial) arteries measured as PWV 
in individuals with T2D and albuminuria. This was not 
observed in patients with T2D but without albuminuria or 
in non-diabetic individuals. Potentially, insulin counteracts 
the vasoconstriction caused by endothelial dysfunction 
and increased sympathetic activity known to be present in 
albuminuric patients with T2D. Interestingly, we observed 
a positive correlation between PWV and postprandial 
serum glucose in the same patients, and only again in the 
patients with albuminuria [9]. Thus, it is possible that in 
albuminuric patients, the arteries are sensitive to acute 
stiffening by glucose, and to relaxation by insulin.
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